OnkoSight AdvancedTM for Myeloid Malignancies
Myeloid malignancies are clonal disorders of the progenitor cells or hematopoietic stem cells, which are comprised of acute stages (e.g., acute myeloid leukemia) and chronic phases including myeloproliferative neoplasms, myelodysplastic disorders, and chronic myelomonocytic leukemia.
Assessment of actionable mutations by next-generation sequencing (NGS) is a powerful tool to define diagnosis, determine prognostic risk, monitor measurable residual disease, and uncover predictive mutational markers and therapeutic targets, and is now a routine component in the workup and monitoring of hematological disorders.
GenPath®, a division of BioReference Health®, LLC, offers a vast menu of NGS panels for myeloid malignancies. Panel inclusive of DNA and RNA genes is also available.
Test Information
Myeloid Complete Panel (148 genes)
Comprehensive Myeloid Panel (75 genes)
TM00-2
ABL1 |
ANKRD26 |
ASXL1 |
ATRX |
BCOR |
BCORL1 |
BRAF |
BTK |
CALR |
CBL |
CBLB |
CBLC |
CCND2 |
CDC25C |
CDKN2A |
CEBPA |
CSF3R |
CUX1 |
CXCR4 |
DCK |
DDX41 |
DHX15 |
DNMT3A |
ETNK1 |
ETV6 |
EZH2 |
FBXW7 |
FLT3 |
GATA1 |
GATA2 |
GNAS |
HRAS |
IDH1 |
IDH2 |
IKZF1 |
JAK2 |
JAK3 |
KDM6A |
KIT |
KMT2A |
KRAS |
LUC7L2 |
MAP2K1 |
MPL |
MYC |
MYD88 |
NF1 |
NOTCH1 |
NPM1 |
NRAS |
PDGFRA |
PHF6 |
PPM1D |
PTEN |
PTPN11 |
RAD21 |
RBBP6 |
RPS14 |
RUNX1 |
SETBP1 |
SF3B1 |
SH2B3 |
SLC29A1 |
SMC1A |
SMC3 |
SRSF2 |
STAG2 |
STAT3 |
TET2 |
TP53 |
U2AF1 |
U2AF2 |
WT1 |
XP01 |
ZRSR2 |
General Myeloid Neoplasm Panel (50 genes)
TL95-4
ABL1 |
ANKRD26 |
ASXL1 |
ATRX |
BCOR |
BCORL1 |
BRAF |
CALR |
CBL |
CCND2 |
CDKN2A |
CEBPA |
CSF3R |
CUX1 |
DDX41 |
DNMT3A |
ETNK1 |
ETV6 |
EZH2 |
FBXW7 |
FLT3 |
GATA2 |
HRAS |
IDH1 |
IDH2 |
JAK2 |
KDM6A |
KIT |
KMT2A |
KRAS |
MAP2K1 |
MPL |
MYD88 |
NF1 |
NPM1 |
NRAS |
PDGFRA |
PHF6 |
PTEN |
PTPN11 |
RUNX1 |
SETBP1 |
SF3B1 |
SRSF2 |
STAG2 |
TET2 |
TP53 |
U2AF1 |
WT1 |
ZRSR2 |
Rapid AML Panel (30 genes)
TL94-7
ASXL1 |
BRAF |
BCOR |
CEBPA |
CSFR3 |
DDX41 |
DNMT3A |
ETV6 |
EZH2 |
FLT3 |
GATA2 |
HRAS |
IDH1 |
IDH2 |
JAK2 |
KIT |
KMT2A |
KRAS |
NF1 |
NPM1 |
NRAS |
PDGFRA |
PHF6 |
PTPN11 |
RUNX1 |
SETBP1 |
STAG2 |
TET2 |
TP53 |
WT1 |
MDS Panel (18 genes)
TL98-8
ASXL1 |
BCOR |
CBL |
DNMT3A |
ETV6 |
EZH2 |
JAK2 |
KRAS |
NRAS |
PTPN11 |
RUNX1 |
SETBP1 |
SF3B1 |
SRSF2 |
TET2 |
TP53 |
U2AF1 |
ZRSR2 |
MPN Panel (17 genes)
TL96-2
ABL1 |
ASXL1 |
CALR |
CBL |
CSF3R |
DNMT3A |
EZH2 |
IDH1 |
IDH2 |
JAK2 |
KIT |
MPL |
SETBP1 |
SF3B1 |
SRSF2 |
TP53 |
U2AF1 |
MPN Cascade Sequencing Panel (3 genes)**
TL97-0
JAK2 |
CALR |
MPL |
++ Analyzed and reported in serial fashion until a mutation is found (JAK2 V617F if negative reflex to CALR, if negative reflex to MPL, if negative reflex to JAK2 exon 12).
JAK2, CALR,MPL, if negative reflex to Myeloid Panel (see TL95 gene components)
TM07-7
CALR |
JAK2 |
MPL |
GenPath also offers singe-gene testing. Healthcare providers should only panels if each gene or test in the panel is medically necessary.